Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis.

Konwar M, Bose D, Jaiswal SK, Maurya MK, Ravi R

International journal of clinical practice19 Jul 2022Cited by 29 (Europe PMC)

PMID35936066PMCIDPMC9325632DOI10.1155/2022/1201977PepBankPUB-35936066

Summary

BackgroundLiraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.ObjectivesObjectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status.MethodsWe conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.ResultsWe compared the pooled estimate of the study results between liraglutide 3.0 mg groups and placebo groups both in diabetic and nondiabetic patients. The efficacy outcomes that were found to be significant among respective studies involving nondiabetic patients vs. diabetic patients were mean change in body weight from baseline: 12 studies [MD = -5.04 kg (95% CI = -5.60, -4.49), P I ² = 92.95%] vs. 2 studies [MD = -4.14 kg (95% CI = -4.95, -3.32), P I ² = 0%], reduction in waist circumference from baseline: 8 studies [MD = -3.64 cm (95% CI = -4.43, -2.85), P I ² = 96.5%] vs. 2 studies [MD = -3.11 cm (95% CI = -3.88, -2.34), P I ² = 0%], BMI reduction from baseline: 5 studies [MD = -1.95 kg/m² (95% CI = -2.22, -1.68) vs. 1 study [MD = -1.86 kg/m² (95% CI = -2.14, -1.57), P I ² = 0%, P I ² = 95.6%], proportion of patients losing more than 5% of weight loss from baseline: 8 studies [RR = 2.21, (95% CI = 1.89, 2.58), P=0.03, I ² = 59.02%] vs. 2 studies [RR = 2.34, (95% CI = 1.93, 2.85), P=0.39, I ² = 0.00%], and 10% weight loss from baseline: 7 studies [RR = 3.36, (95% CI = 1.92, 5.91), P=0.00, I ² = 87.03%] vs. 2 studies [RR = 3.64, (95% CI = 2.46, 5.40), P=0.81, I ² = 0.00%]. Safety outcome assessment with use of liraglutide 3.0 mg compared with placebo in respective nondiabetic vs. diabetic patients revealed significant proportion of patients experiencing the adverse events: 9 studies [RR = 1.11, (95% CI = 1.04, 1.18), P=0.00I ² = 79.15%] vs. 2 studies [RR = 1.06, (95% CI = 1.01, 1.11), P=0.42, I ² = 0.03%] but similar risk of serious adverse events: 9 studies [RR = 1.03, (95% CI = 0.70, 1.51), P=0.26, I ² = 18.54%] vs. 2 studies [RR = 1.11, (95% CI = 0.67, 1.84), P=0.25, I ² = 23.77%] and TDAEs: 4 studies [RR = 0.89, (95% CI = 0.35, 2.28), P=0.03, I ² = 61.89%] vs. 1 study [RR = 2.53, (95% CI = 1.00, 6.37)]. However, the pooled estimates irrespective of the glycaemic status were mean change in body weight from baseline: 14 RCT [MD = -4.91 kg (95% CI = -5.43, -4.39), P I ² = 92.35%], reduction in waist circumference from baseline: 10 studies [MD = -3.55 cm, (95% CI = -4.21, -2.89), P I ² = 94.99%], BMI reduction from baseline: 6 studies [MD = -1.86 kg/m², (95% CI = -2.14, -1.57), P I ² = 96.14%], and proportion of patients losing more than 5% and 10% of weight from baseline: [RR = 2.23, (95% CI = 1.98, 2.52), P I ² = 48.87%] and [RR = 3.28, (95% CI = 2.23, 4.83), P I ² = 78.98%], respectively. Also, the proportion of patients experiencing the adverse event was more with liraglutide 3.0 mg compared with placebo 11 study [RR = 1.09, (95% CI = 1.04, 1.15), P I ² = 76.60%] and similar risk for both serious adverse events: 11 studies [RR = 1.09, (95% CI = 1.04, 1.15), P I ² = 76.60%] and TDAEs: 5 studies [RR = 1.14, (95% CI = 0.50, 2.60), P I ² = 64.93%] with liraglutide compared with placebo.ConclusionsLiraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or obesity regardless of diabetic status compared to placebo.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study24

24 results from studies that gave the peptide. 24 results from people.

01HumanSystematic reviewEfficacy outcome
In nondiabetic patients with overweight or obesity, liraglutide 3.0 mg reduced body weight from baseline versus placebo.
In plain wordsIn people with overweight or obesity and no diabetes, liraglutide 3.0 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseChange in body weight from baseline, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−5.04 kg
nondiabetic, 12 studies
Source sentences
Summary
mean change in body weight from baseline: 12 studies [MD = -5.04 kg (95% CI = -5.60, -4.49), P I ² = 92.95%] vs. 2 studies [MD = -4.14 kg (95% CI = -4.95, -3.32)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606601
02HumanSystematic reviewEfficacy outcome
In patients with diabetes and overweight or obesity, liraglutide 3.0 mg reduced body weight from baseline versus placebo.
In plain wordsIn people with overweight or obesity and diabetes, liraglutide 3.0 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseChange in body weight from baseline, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−4.14 kg
diabetic, 2 studies
Source sentences
Summary
mean change in body weight from baseline: 12 studies [MD = -5.04 kg (95% CI = -5.60, -4.49), P I ² = 92.95%] vs. 2 studies [MD = -4.14 kg (95% CI = -4.95, -3.32)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606602
03HumanSystematic reviewEfficacy outcome
Irrespective of glycaemic status, liraglutide 3.0 mg reduced body weight from baseline versus placebo in patients with overweight or obesity.
In plain wordsIn people with overweight or obesity, with or without diabetes, liraglutide 3.0 mg reduced body weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseChange in body weight from baseline, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−4.91 kg
14 RCTs
Source sentences
Summary
mean change in body weight from baseline: 14 RCT [MD = -4.91 kg (95% CI = -5.43, -4.39)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606603
04HumanSystematic reviewEfficacy outcome
In nondiabetic patients with overweight or obesity, liraglutide 3.0 mg reduced waist circumference from baseline versus placebo.
In plain wordsIn people with overweight or obesity and no diabetes, liraglutide 3.0 mg reduced waist size more than placebo.
Peptide
Liraglutide
Outcome
DecreaseReduction in waist circumference, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−3.64 cm
nondiabetic, 8 studies
Source sentences
Summary
reduction in waist circumference from baseline: 8 studies [MD = -3.64 cm (95% CI = -4.43, -2.85), P I ² = 96.5%] vs. 2 studies [MD = -3.11 cm (95% CI = -3.88, -2.34)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606604
05HumanSystematic reviewEfficacy outcome
In patients with diabetes and overweight or obesity, liraglutide 3.0 mg reduced waist circumference from baseline versus placebo.
In plain wordsIn people with overweight or obesity and diabetes, liraglutide 3.0 mg reduced waist size more than placebo.
Peptide
Liraglutide
Outcome
DecreaseReduction in waist circumference, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−3.11 cm
diabetic, 2 studies
Source sentences
Summary
reduction in waist circumference from baseline: 8 studies [MD = -3.64 cm (95% CI = -4.43, -2.85), P I ² = 96.5%] vs. 2 studies [MD = -3.11 cm (95% CI = -3.88, -2.34)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606605
06HumanSystematic reviewEfficacy outcome
Irrespective of glycaemic status, liraglutide 3.0 mg reduced waist circumference from baseline versus placebo in patients with overweight or obesity.
In plain wordsIn people with overweight or obesity, with or without diabetes, liraglutide 3.0 mg reduced waist size more than placebo.
Peptide
Liraglutide
Outcome
DecreaseReduction in waist circumference, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−3.55 cm
10 studies
Source sentences
Summary
reduction in waist circumference from baseline: 10 studies [MD = -3.55 cm, (95% CI = -4.21, -2.89)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606606
07HumanSystematic reviewEfficacy outcome
In nondiabetic patients with overweight or obesity, liraglutide 3.0 mg reduced BMI from baseline versus placebo.
In plain wordsIn people with overweight or obesity and no diabetes, liraglutide 3.0 mg lowered BMI more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−1.95 kg/m2
nondiabetic, 5 studies
Source sentences
Summary
BMI reduction from baseline: 5 studies [MD = -1.95 kg/m² (95% CI = -2.22, -1.68) vs. 1 study [MD = -1.86 kg/m² (95% CI = -2.14, -1.57)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606607
08HumanSystematic reviewEfficacy outcome
In patients with diabetes and overweight or obesity, liraglutide 3.0 mg reduced BMI from baseline versus placebo.
In plain wordsIn people with overweight or obesity and diabetes, liraglutide 3.0 mg lowered BMI more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−1.86 kg/m2
diabetic, 1 study
Source sentences
Summary
BMI reduction from baseline: 5 studies [MD = -1.95 kg/m² (95% CI = -2.22, -1.68) vs. 1 study [MD = -1.86 kg/m² (95% CI = -2.14, -1.57)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606608
09HumanSystematic reviewEfficacy outcome
Irrespective of glycaemic status, liraglutide 3.0 mg reduced BMI from baseline versus placebo in patients with overweight or obesity.
In plain wordsIn people with overweight or obesity, with or without diabetes, liraglutide 3.0 mg lowered BMI more than placebo.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
MD
−1.86 kg/m2
6 studies
Source sentences
Summary
BMI reduction from baseline: 6 studies [MD = -1.86 kg/m², (95% CI = -2.14, -1.57)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606609
10HumanSystematic reviewEfficacy outcome
In nondiabetic patients with overweight or obesity, more patients lost more than 5% of weight with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity and no diabetes, more people lost over 5% of their weight with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion losing more than 5% of weight, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
2.21 NA
nondiabetic, 8 studies
Source sentences
Summary
proportion of patients losing more than 5% of weight loss from baseline: 8 studies [RR = 2.21, (95% CI = 1.89, 2.58), P=0.03, I ² = 59.02%] vs. 2 studies [RR = 2.34, (95% CI = 1.93, 2.85)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606610
11HumanSystematic reviewEfficacy outcome
In patients with diabetes and overweight or obesity, more patients lost more than 5% of weight with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity and diabetes, more people lost over 5% of their weight with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion losing more than 5% of weight, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
2.34 NA
diabetic, 2 studies
Source sentences
Summary
proportion of patients losing more than 5% of weight loss from baseline: 8 studies [RR = 2.21, (95% CI = 1.89, 2.58), P=0.03, I ² = 59.02%] vs. 2 studies [RR = 2.34, (95% CI = 1.93, 2.85)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606611
12HumanSystematic reviewEfficacy outcome
Irrespective of glycaemic status, more patients lost more than 5% of weight with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity, with or without diabetes, more people lost over 5% of their weight with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion losing more than 5% of weight, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
2.23 NA
pooled
Source sentences
Summary
proportion of patients losing more than 5% and 10% of weight from baseline: [RR = 2.23, (95% CI = 1.98, 2.52)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606612
13HumanSystematic reviewEfficacy outcome
In nondiabetic patients with overweight or obesity, more patients lost 10% of weight with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity and no diabetes, more people lost 10% of their weight with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion losing 10% of weight, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
3.36 NA
nondiabetic, 7 studies
Source sentences
Summary
and 10% weight loss from baseline: 7 studies [RR = 3.36, (95% CI = 1.92, 5.91), P=0.00, I ² = 87.03%] vs. 2 studies [RR = 3.64, (95% CI = 2.46, 5.40)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606613
14HumanSystematic reviewEfficacy outcome
In patients with diabetes and overweight or obesity, more patients lost 10% of weight with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity and diabetes, more people lost 10% of their weight with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion losing 10% of weight, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
3.64 NA
diabetic, 2 studies
Source sentences
Summary
and 10% weight loss from baseline: 7 studies [RR = 3.36, (95% CI = 1.92, 5.91), P=0.00, I ² = 87.03%] vs. 2 studies [RR = 3.64, (95% CI = 2.46, 5.40)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606614
15HumanSystematic reviewEfficacy outcome
Irrespective of glycaemic status, more patients lost 10% of weight with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity, with or without diabetes, more people lost 10% of their weight with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion losing 10% of weight, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
3.28 NA
pooled
Source sentences
Summary
and [RR = 3.28, (95% CI = 2.23, 4.83)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606615
16HumanSystematic reviewSafety outcome
In nondiabetic patients, a larger proportion had adverse events with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity and no diabetes, more people had side effects with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseAdverse events, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
1.11 NA
nondiabetic, 9 studies
Source sentences
Summary
experiencing the adverse events: 9 studies [RR = 1.11, (95% CI = 1.04, 1.18), P=0.00I ² = 79.15%] vs. 2 studies [RR = 1.06, (95% CI = 1.01, 1.11)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606616
17HumanSystematic reviewSafety outcome
In patients with diabetes, a larger proportion had adverse events with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity and diabetes, more people had side effects with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseAdverse events, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
1.06 NA
diabetic, 2 studies
Source sentences
Summary
experiencing the adverse events: 9 studies [RR = 1.11, (95% CI = 1.04, 1.18), P=0.00I ² = 79.15%] vs. 2 studies [RR = 1.06, (95% CI = 1.01, 1.11)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606617
18HumanSystematic reviewSafety outcome
Irrespective of glycaemic status, a larger proportion had adverse events with liraglutide 3.0 mg than with placebo.
In plain wordsIn people with overweight or obesity, with or without diabetes, more people had side effects with liraglutide 3.0 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseAdverse events, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
1.09 NA
11 studies
Source sentences
Summary
the proportion of patients experiencing the adverse event was more with liraglutide 3.0 mg compared with placebo 11 study [RR = 1.09, (95% CI = 1.04, 1.15)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606618
19HumanSystematic reviewSafety outcome
In nondiabetic patients, the risk of serious adverse events was similar with liraglutide 3.0 mg and placebo.
In plain wordsIn people with overweight or obesity and no diabetes, serious side effects were about as likely with liraglutide 3.0 mg as with placebo.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
1.03 NA
nondiabetic, 9 studies
Source sentences
Summary
similar risk of serious adverse events: 9 studies [RR = 1.03, (95% CI = 0.70, 1.51), P=0.26, I ² = 18.54%] vs. 2 studies [RR = 1.11, (95% CI = 0.67, 1.84)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606619
20HumanSystematic reviewSafety outcome
In patients with diabetes, the risk of serious adverse events was similar with liraglutide 3.0 mg and placebo.
In plain wordsIn people with overweight or obesity and diabetes, serious side effects were about as likely with liraglutide 3.0 mg as with placebo.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
1.11 NA
diabetic, 2 studies
Source sentences
Summary
similar risk of serious adverse events: 9 studies [RR = 1.03, (95% CI = 0.70, 1.51), P=0.26, I ² = 18.54%] vs. 2 studies [RR = 1.11, (95% CI = 0.67, 1.84)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606620
21HumanSystematic reviewSafety outcome
Irrespective of glycaemic status, the abstract reports a similar risk of serious adverse events with liraglutide 3.0 mg and placebo.
In plain wordsIn people with overweight or obesity, with or without diabetes, serious side effects were about as likely with liraglutide 3.0 mg as with placebo.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
serious adverse events: 11 studies [RR = 1.09, (95% CI = 1.04, 1.15)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606621
22HumanSystematic reviewSafety outcome
In nondiabetic patients, the risk of TDAEs was similar with liraglutide 3.0 mg and placebo.
In plain wordsIn people with overweight or obesity and no diabetes, the risk of this side-effect outcome was similar with liraglutide 3.0 mg and placebo.
Peptide
Liraglutide
Outcome
No significant changeTDAEs, nondiabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
0.89 NA
nondiabetic, 4 studies
Source sentences
Summary
TDAEs: 4 studies [RR = 0.89, (95% CI = 0.35, 2.28), P=0.03, I ² = 61.89%] vs. 1 study [RR = 2.53, (95% CI = 1.00, 6.37)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606622
23HumanSystematic reviewSafety outcome
In patients with diabetes, one study reported a similar risk of TDAEs with liraglutide 3.0 mg and placebo (RR 2.53, 95% CI 1.00 to 6.37).
In plain wordsIn people with overweight or obesity and diabetes, one study reported a similar risk of this side-effect outcome with liraglutide 3.0 mg and with placebo.
Peptide
Liraglutide
Outcome
No significant changeTDAEs, diabetic patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
2.53 NA
diabetic, 1 study
Source sentences
Summary
TDAEs: 4 studies [RR = 0.89, (95% CI = 0.35, 2.28), P=0.03, I ² = 61.89%] vs. 1 study [RR = 2.53, (95% CI = 1.00, 6.37)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606623
24HumanSystematic reviewSafety outcome
Irrespective of glycaemic status, the risk of TDAEs was similar with liraglutide 3.0 mg and placebo.
In plain wordsIn people with overweight or obesity, with or without diabetes, the risk of this side-effect outcome was similar with liraglutide 3.0 mg and placebo.
Peptide
Liraglutide
Outcome
No significant changeTDAEs, all patients
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
3.0 mg daily · subcutaneousAs given in this study (human).
Measurements
RR
1.14 NA
5 studies
Source sentences
Summary
TDAEs: 5 studies [RR = 1.14, (95% CI = 0.50, 2.60)
2 context sentences(design, population, supporting numbers)
Summary · context
Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction.
Summary · context
We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m²) and obese (≥30 kg/m²) patients above 18 years of age.
Show in the study text Report a problemFND-3593606624

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.